There is an increasing demand by patients and desire by physicians to utilize adjunctive medications in type 1 diabetes. Many patients with type 1 diabetes who are highly likely to benefit from the weight loss and cardiorenal risk reduction effects of these drugs are denied access to them because of putative safety concerns and a dearth of clinical trial evidence in type 1 diabetes. Identifying patients with type 1 diabetes most likely to tolerate and benefit from these agents is a research priority. Real world datasets accounting for the increased off license use of these drugs offers an opportunity to rapidly develop evidence-based guidance.
Luk et al. (Thu,) studied this question.